Liu Tao, general manager of Guosheng Investment Bao Yashan Valley: Industrial Park drives pharmaceutical innovation into the development expressway

Biomedicine is one of the three pilot industries that Shanghai wants to "concentrate the elite strength and accelerate the breakthrough". Although after years of development, the development scale and level of Shanghai biomedical industry have been at the forefront of the country, and have accumulated a number of innovative results and hatched a number of leading enterprises. With world -class biomedical industry cluster.

The "Fourteenth Five -Year Plan for the Development of the Biomedical Industry in Shanghai" clearly stated that by 2025, the initial construction of the core of the world -class biopharmaceutical industry cluster bearing place. The city's biomedical industry scale exceeds 100 billion yuan.

The Biomedical Industrial Park is an important carrier and starting point for Shanghai to impact trillion targets. At present, Shanghai has also clearly planned the "1+5+X" biomedical industry space layout.

Among them, North Shanghai Biomedical Industrial Park is one of the five major city -level biomedical characteristic industrial parks. Since being awarded the title of "Shanghai Featured Industrial Park", Baoshan Biomedical Industry has also entered a fast track of high -speed development. According to the 21st Century Business Herald reporter, North Shanghai Biomedical Industrial Park has built high -quality biomedical public engineering facilities and integrated solutions through the construction of high -quality biomedicine research and development and industrialized carrier space to create high -quality biomedical innovation and development ecosystems and ecology and ecology and ecology and ecology and ecology and Professional service system, focusing on cultivating and developing high -value -added "biological products, medical devices, original innovative drugs", and introduced key links of enterprise headquarters, R & D centers, high -end production and industrial chain.

Recently, in the special online forum of the national online forum, which was initiated by the Southern Finance and Economics Group, the 21st Century Business Herald and the 21st Century New Health Research Institute's "Shouhu New Student Creation of the Future -Help Shanghai to create a world -class biomedical industry cluster" Liu Tao, general manager of Bao Yashan Valley, made a special sharing on "How to help the high -quality development of the biomedical industry?"

Please introduce it to us that the industrial positioning of Baoshan MP, including the current segmentation of Baoshan MPs and which areas will be focused on in the future and which pharmaceutical industries will be cultivated?

Liu Tao: Since March 2020, North Shanghai Biomedical Industrial Park has been awarded the title of "Shanghai Featured Industrial Park" and has become one of the five major city -level biomedical characteristic industrial parks. Essence As a major project in Shanghai, Baoshan MP is constructed with professional biomedical carriers. The total planning area of ​​Baoshan MPI is 200 acres, and the first phase of 100 acres is under construction. In September this year, some factory buildings have been delivered. In the process, we realize that the professionalism, characteristic and high quality of medical professional carriers are very important. In our industrial direction, we focus on focusing on cell therapy, gene therapy and nucleic acid drugs.

In your opinion, what factors will the company consider when choosing to settle in Baoshan MP? Can you ask for an example? From the perspective of the current resource equipment, what are the convenience and support of the enterprise after entering?

Liu Tao: Baoshan MPs is a major project in Shanghai. In 2020, Shanghai planned a "1+5+X" biomedical industry layout. The North Shanghai Biomedical Industrial Park where Baoshan Yaogu is located, as one of the "5", undertakes the heavy responsibility of developing the biomedical industry. Baoshan Yaogu was constructed in October 2020. At the beginning of the design, the leaders of the municipal and district -level leaders asked us what the needs of biomedical companies? What are the characteristics of the characteristic future development of the biomedical park? In the process of this study, we have considered many details from the needs. For example, the company first considers the needs of the location before settling. During the location of the enterprise, the environment and atmosphere around Baoshan MPI have good resources and environmental advantages. Secondly, in terms of professional carriers, there must be professional quality guarantee requirements. In addition, in terms of talent density, because pharmaceutical companies are industries with dense capital, human -intensive, and intensive knowledge. So talent density is important, which is also the advantage of Shanghai. In terms of location selection, it will also take into account the professional service capabilities at the park level, and the level of understanding or mutual trust of the service of services is very important.

Once a biomedical enterprise is implemented for a long time, the company is very concerned about policy support during the location of the enterprise. Supporting and superimposed, these aspects are very important and have good promotion value when selecting the location of the enterprise.

There are also different investment promotion strategies for different enterprises. Compared with other parks or platforms, what are the differences between Baoshiyama Valley for enterprise talent introduction, investment and financing support, and research and development laboratory. How to look at the differentiation of parks such as Lingang, Oriental Mei Valley, Zhangjiang Yaogu and other parks?

Liu Tao: The current development of the biomedical industry is still relatively good. The needs of Shanghai biomedical carriers have sufficient quantities. We should say that cooperation is greater than competition. In addition, the industrial field of biomedicine is very extensive, with professional tracks and professional services. This is also a good misalignment choice. We have a daily contact mechanism. At the same time, because we are the investment management platform of Shanghai Guosheng Group Park Park Park, , Guosheng Investment has invested in the construction of Baoshiyama Valley through funding, so we have strong financial genes that are easier to cooperate with venture capital institutions. What can the company really get after entering Baoshan MP? Specifically, including the following three aspects: First, public engineering facilities can provide low -cost services, saving everyone's daily operating costs;

Second, we have environmental management housekeeper, security butler, property housekeeper, and laboratory housekeeper to directly docking and steward services in the project. This is based on government supervision and approval behavior. Our park will provide good services;

Third, in -depth market -oriented services, including our investment services just now, services of financing docking banks and financial institutions, and professional industrial chain services such as some public laboratories construction.

At present, promoting innovation research and development has also become a focus of domestic innovative pharmaceutical companies, and many innovative pharmaceutical companies have emerged to focus on FIRST-In-Class products. In your opinion, an innovative enterprise can develop in the long run. What is the key element? How to achieve high -quality development?

Liu Tao: Now we have communication and cooperation with biomedical companies in different life cycles. In the process, we feel that the current situation of biomedical development has a high challenge to the biomedical team or founder. From small R & D teams to biotechnology companies, to companies that can form biopharmaceuticals, each stage has their own challenges for entrepreneurs. From the perspective of this enterprise development, from two aspects, on the one hand, one -time cost considerations are considered, and on the other hand, the cost issues during long -term stable operation. If the product is listed, the next step may be considered the way of the company's listing, and it is important to open up financing channels. There are also some key points that are policy approval. If companies want high -quality development needs to communicate, consult, and services with government departments and pharmaceutical supervision departments, and realize the license of drug listing as soon as possible. It is also the key to its success.

According to your observation, what is the development situation of Shanghai's biomedical industry after this round of epidemic? What opportunities and challenges exist?

Liu Tao: Biomedical companies in different life cycles can find a good and developed space. I think this is our good foundation. In addition, because of the epidemic situation, we also feel that it still has a certain impact on pharmaceutical companies. The pharmaceutical industry is based on experimental research and development, which requires people to operate in the right space, which also has a great impact on the science of the experimental research and development. In addition, in terms of internationalization of medicine, the international exchanges, internationalization, and industrialization of personnel have been affected. Some customers who exported the United States were delayed, causing the order to be canceled, which also had a direct impact on enterprises. The epidemic has an influence on our confidence. Many investors in the biomedical circle are more cautious. There are a group of high -quality biomedical companies. Because of the caution of investors, the original signing or basic investment may be due to various kinds of investment. The reason delay. Here I call on everyone to support the development of biomedical companies, and to increase our confidence at the same time. In the future, Shanghai will also be the highlands of the development of the biomedical industry. The biomedical industry will still be the rising industry that will never end.

Under the influence of the epidemic, the emergence of these pharmaceutical industrial parks represented by Baoshan MPs is helpful for building the Yangtze River Delta biomedical industry cluster?

Liu Tao: We have clearly become an important carrying area of ​​the Shanghai Science and Technology Innovation Center. From the perspective of Pokémon Valley in promoting the development of biomedicine, we will solve the problem from the unique and personalized way of each company. For example, in response to the issues of enterprises in financing, we coordinate the support of banking institutions and increase the efforts of investment docking. In addition, we will have a very good communication mechanism with the government, which can realize the advance payment of policies as soon as possible to optimize the cash flow situation. In addition, we are also doing some efforts to help enterprises provide support for rent payment and property sales to provide support. Through various efforts to achieve the growth of a company company and help every company cross the difficulties. I think this is our success and our main point.

- END -